1282P Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naïve advanced ALK+ NSCLC from the ALTA-1L trial
| Autor: | Mezquita, L., Laguna Montes, J.C., Ferriol-Galmés, M., Albarran Artahona, V.M., García Pardo de Santayana, M., Gorría Puga, T., Crous Bruñol, C., Jiménez, M., Bernabeu Aracil, M.B., Navarro Mendivil, A.F., Reguart Aransay, N., Arcocha, A., Teixido, C., Dingemans, A-M.C., Auclin, E. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S818-S818 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|